News
VANI
1.620
-0.61%
-0.010
Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Signet Jewelers Limited shares dipped 12.5% to $94.81 on Thursday. The company reported mixed first-quarter earnings. Elon Musk's Tesla Inc. Shares rose 6% after posting better-than-expected quarterly results on Wednesday. Gainers BioRestorative Therapies, Inc. And Barnes & Noble Education also rose in the mid-day.
Benzinga · 18h ago
BUZZ-U.S. STOCKS ON THE MOVE-ACI Worldwide, enCore Energy, Adobe
S&P 500 and Dow indexes slip as investors weigh hawkish Fed projections against data signaling cooling inflation. Strength in chip stocks supported the Nasdaq. The Dow Jones Industrial Average was down 0.35% at 38,576.01. The top three Nasdaq percentage gainers were Broadcom and Barnes & Noble.
Reuters · 18h ago
BUZZ-U.S. STOCKS ON THE MOVE-Williams-Sonoma, ACI Worldwide, enCore Energy
S&P 500 and Nasdaq indexes hit record highs on Thursday. Chip stocks jump after lower-than-forecast producer inflation data fanned expectations of interest-rate cuts from the Fed. Dow Jones Industrial Average down 0.51% to 38,513.74; Nasdaq up 0.23%.
Reuters · 20h ago
Why GLP-1 Developer Vivani Medical's Stock Is Climbing
Vivani Medical, Inc. Shares are trading higher after the company announced the FDA cleared the Investigational New Drug application and lifted the clinical hold on NPM-119. Vivani shares are moving on heavy trading volume following the company's announcement. More than 11.7 million shares have already been traded in the session. The company is developing a miniature implant for type 2 diabetes.
Benzinga · 20h ago
Vivani Medical Shares Up, FDA Cleared New Drug Application to Start Diabetes Trial
Dow Jones · 21h ago
VIVANI MEDICAL SHARES UP 14% AS US FDA LIFTS CLINICAL HOLD ON TRIAL FOR DIABETES TREATMENT IMPLANT
Reuters · 22h ago
BUZZ-U.S. STOCKS ON THE MOVE-Vivani, Vanda, Sarepta
Futures tracking the Nasdaq leapt on Thursday on gains in heavyweight technology stocks. The Federal Reserve is expected to ease interest rates in September despite projecting just one cut this year. The top two NYSE percentage gainers premarket were John Wiley and Vanda Pharmaceuticals. Virgin Galactic was the top Nasdaq percentage loser.
Reuters · 22h ago
Vivani Medical gains as FDA lifts clinical hold on GLP-1 implant
Vivani Medical gains as FDA lifts clinical hold on GLP-1 implant. Shares of Vivani Medical added ~10% premarket Thursday. The U.S. FDA lifted the clinical hold on NPM-119, a medical implant designed to deliver GLp-1 receptor agonist.
Seeking Alpha · 23h ago
BUZZ-Vivani jumps as US FDA lifts clinical hold on trial for diabetes treatment implant
Reuters · 23h ago
IVivani Medical Gets FDA Clearance to Start Trial of GLP-1 Implant for Diabetes
Dow Jones · 23h ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Longeveron (NASDAQ:LGVN) stock rose 30.9% to $2.37 during Thursday's pre-market session. JanOne stock rose 26.07% and Vivani Medical stock rose 15.9%. Losers Assure Hldgs stock fell 46.4% and Cara Therapeutics shares decreased by 31.19% during the session.
Benzinga · 1d ago
VIVANI MEDICAL ANNOUNCES FDA CLEARS INVESTIGATIONAL NEW DRUG APPLICATION AND LIFTS CLINICAL HOLD FOR NPM-119, A MINIATURE LONG-TERM SUBDERMAL GLP-1 DRUG IMPLANT
Reuters · 1d ago
EXCLUSIVE: Vivani Medical's Type 2 Diabetes Treatment NPM-119 Subdermal Implant's NDA Gains FDA Clearance For Clinical Use
Benzinga · 1d ago
Weekly Report: what happened at VANI last week (0603-0607)?
Weekly Report · 4d ago
Weekly Report: what happened at VANI last week (0527-0531)?
Weekly Report · 06/03 11:25
VIVANI MEDICAL ANNOUNCES PUBLICATION OF POSITIVE WEIGHT LOSS DATA SUPPORTING POTENTIAL VETERINARY USE OF OKV-119 MINIATURE, LONG-TERM GLP-1 IMPLANT
Reuters · 05/28 12:00
EXCLUSIVE: Vivani Medical Highlights Weight Loss Data For GLP-1 Implant Supporting Potential Veterinary Use
Vivani Medical reports positive proof-of-concept weight loss data with OKV-119 to treat feline obesity and diabetes in the peer-reviewed BMC Veterinary Research. The company is developing a miniature, subdermal, exenatide drug implant for the treatment.
Benzinga · 05/28 11:30
Weekly Report: what happened at VANI last week (0520-0524)?
Weekly Report · 05/27 11:30
Weekly Report: what happened at VANI last week (0513-0517)?
Weekly Report · 05/20 11:22
Buy Rating Justified: Vivani Medical’s Promising NPM-115 Implant and Strategic Market Positioning
TipRanks · 05/15 16:35
More
Webull provides a variety of real-time VANI stock news. You can receive the latest news about Vivani Medical through multiple platforms. This information may help you make smarter investment decisions.
About VANI
Vivani Medical, Inc. is a preclinical-stage biopharmaceutical company. The Company develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. It is engaged in the development of the Company’s lead programs NPM-115 and NPM-119, is a GLP-1 implant candidates for the treatment of chronic weight management and patients with type 2 diabetes, respectively. Its other pipeline product candidates include NPM-139, and OKV-119. It uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. It operates through two segments: Biopharm Division and Neuromodulation Division. The Company’s implant technology, which it refers as NanoPortal, utilizes a space-efficient design that allows a miniaturized implant to provide many months of therapeutic delivery of potent molecules.